This article was originally published in The Tan Sheet
Australia's Therapeutic Goods Association is requiring a warning on all products containing black cohosh that reads, "Warning: Black cohosh may harm the liver in some individuals. Use under the supervision of a healthcare professional," the country's government announces Feb. 9. TGA reviewed the safety of black cohosh to find 47 cases of liver reactions worldwide, including nine cases in Australia. "Considering the widespread use of black cohosh, the incidence of liver reaction appears to be very low," TGA states. However, four of the nine Australians who suffered liver problems were hospitalized and two required transplants. New products must comply with the requirement from the time of their launch, but existing products have a 12-month phase-in period...
You may also be interested in...
The UK's Medicines & Healthcare products Regulatory Agency (MHRA) will add warnings to black cohosh products about the risk of liver disorders associated with use of the herbal, the agency states in a release July 18
Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.